Natreon
CompanyUnited StatesFounded 1998
Natreon develops one asset, in phase 2 (Sensoril in generalized anxiety disorder). Mostly supplement acting on Oxidative stress and ROS signalling and inflammation; based in the United States, founded in 1998.
- 1
- Asset
- Furthest stage
- Phase 2
- 1
- Trial
- 0
- Signals
Pipeline
1Standardized Withania somnifera extract with adaptogenic and GABAergic modulation effects
Phase 2, Supplement, Oxidative stress and ROS signalling, Inflammation, generalized anxiety disorder
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials1
- Similar companies6